Integrated Computational Investigation of Cannabis sativa Phytoconstituents as Putative Multi-Target Inhibitors in

Lamiae El Bouamri1, Salma Laaouina1, Ibtissam Lakrim1

  • 1Laboratory of Analytical and Molecular Chemistry, Faculty of Sciences Ben M'Sick, Hassan II University of Casablanca, Casablanca 20670, Morocco.

PubMed

Insights

Cannabis sativa compounds show potential for treating skin cancer by inhibiting key signaling pathways like EGFR, BRAF V600E, and TGF-β. This computational study identifies promising natural modulators for targeted cancer therapy.

Area of Science:

  • Oncology
  • Pharmacology
  • Computational Chemistry

Background:

  • Skin cancer progression involves dysregulated oncogenic signaling pathways, including EGFR, BRAF V600E, and TGF-β.
  • These pathways drive tumor proliferation, invasion, and metastasis.
  • Multitarget natural modulators offer a promising therapeutic strategy for skin cancer.

Purpose of the Study:

  • To computationally evaluate phytoconstituents from Cannabis sativa for their potential to inhibit EGFR, BRAF V600E, and TGF-β receptor.
  • To assess the binding affinities, interactions, and pharmacokinetic properties of these compounds.

Main Methods:

  • Integrated computational approach including molecular docking and ADMET analysis.
  • Evaluation of 49 phytoconstituents from Cannabis sativa against target proteins.
  • Molecular dynamics simulations and MM-GBSA calculations for stability and binding energetics.

Main Results:

  • Several Cannabis sativa phytoconstituents demonstrated strong binding affinities and stable interactions with target proteins.
  • Compounds exhibited favorable pharmacokinetic profiles and acceptable safety characteristics.
  • Molecular dynamics and MM-GBSA confirmed the stability and favorable energetics of protein-ligand complexes.

Conclusions:

  • Cannabis sativa phytoconstituents are a potential source of multitarget modulators for skin cancer.
  • These compounds can attenuate EGFR, BRAF V600E, and TGF-β driven oncogenic signaling.
  • The study provides a basis for further in vitro validation and development of cannabis-derived therapeutics.

Related Concept Videos

Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids01:24

CNS Stimulants: Cocaine, Amphetamines and Cannabinoids

CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its effects by...
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Drug Concentrations: Measurements01:23

Drug Concentrations: Measurements

Drug concentration is the quantity of a drug present in a biological sample. Measuring drug amounts in biological samples allows the clinician to understand how a drug is absorbed, distributed, metabolized, and excreted. Samples can be obtained through invasive or non-invasive methods. Invasive techniques involve surgical or parenteral interventions to gather blood, cerebrospinal fluid, or tissue biopsy. Conversely, non-invasive approaches provide samples like urine, feces, and saliva.
Plasma —...